Report Overview

Global Antidiabetics Market – Market Outlook & Trends 

The Global Antidiabetics Market estimated at USD 63.5 billion in 2019, is expected to reach USD 121.40 Billion in 2026, at a CAGR of 9.70 % during the projection period. The prevalence of diabetes among increasing individuals across the globe, the requirement for treatment without side effects and rising acceptance antidiabetic drugs, in emerging and advanced nations drive the market for antidiabetic drugs. The strong growth of antidiabetics is mainly attributed to its advantages and functioning that allow fewer chances of severe glycemic conditions because of limited glucose variability. Besides, the ability of antidiabetic pumps to store data can be further used to analyze data in determining treatment schedules. Such advantages are likely to induce the antidiabetics market. The pharma companies spend substantially on R & D for drug development to discover medicines with minimal side effects providing impetus to the market.

Global Antidiabetics Market – Overview 

Diabetes is a long-lasting metabolic disease wherein the body is either unable to produce insulin (Type-1) or cannot absorb insulin (Type-2). Diabetes is one kind of metabolic illness in which the individual has high blood glucose (blood sugar) due to insufficient insulin production or the body's cells not responding well to insulin. Patients with high sugar levels experience various symptoms such as increased thirst (polydipsia), weight loss, augmented hunger (polyphagia), and recurrent and sweet-smelling urination (polyuria). If it is not cured within time, diabetes causes various severe and chronic life-threatening complications.

Diabetes may occur in any age irrespective of gender. Overweight people with unhealthy diets and less physical activity are more prone to diabetes. Diabetes may lead to many severe conditions such as sightlessness, amputations, kidney failure, and advanced risk of death. The anti-diabetics market comprises drugs used for curing diabetes mellitus, and, these drugs are known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has developed remarkably over the current years due to the growing occurrence of diabetes mellitus. Thus, complete treatment for diabetes has become the focal point of care due to the burgeoning diabetic ailments among all age groups, including middle age groups and children across all income clusters globally.

Drivers 

Growing investment in drug development to manage diabetes

According to the European Society of Cardiology, the diabetic population is expected to reach 628.6 million by 2045. The treatment of diabetes needs appropriate interference and drug administration as per the conditions of patients. Advancement in antidiabetic drugs has led to maximum success rates and fewer difficulties. And due to that, numerous new drugs including, dipeptidyl peptidase-4 inhibitors, discriminatory sodium-glucose cotransporter-2 inhibitors and exclusive peroxisome proliferator-activated receptor agonists are in the growth stage. Besides, the introduction of new devices has improved the chances for combination treatments. The public and structural efforts to innovate diabetes drugs expand the market size immediately. 

High success rates associated with insulin antidiabetic products 

The success rate associated with insulin products is expected to provide high market potential. The drug segment is sub-categorized into Alpha-glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors and Thiazolidinedione. The edge of short-acting analog has improved its post-prandial glucose-controlling ability in type 1 and type 2 diabetic patients and, the segment is likely to witness unparalleled growth during the analysis with a surge in the type-2 diabetic patient pool.

Restraints

The high cost of Antidiabetic Drugs

High costs of diabetes medications do not only compel the patients to live with this condition but also restrict the healthcare capability of medical professionals. Even the most effective antidiabetic medications recommended by the astute and thorough medical professionals are not affordable for a patient with modest income.

Impact of COVID-19 in industry

The COVID-19 eruption has affected nearly 100 countries severely, and it has been declared a Public Health Emergency by WHO. The economies across the world are witnessing slump with a slowdown in every sector. The widespread Coronavirus has also negatively influenced the Antidiabetic Medication market in 2020 by a noticeable decline in demand and production and disrupting supply chains. However, as the Antidiabetic market is related to healthcare, its growth will not be obstructed for a long time due to pandemic.

Global Antidiabetics Market: Segmentation

The AntiDiabetic Market is divided into Insulin segment and Drug segment based on product. Insulin segment is again divided into fast-acting analog, long-acting analog, premixed insulin, short-acting analog, middle acting insulin segments. The Insulin segment secured a notable market share in 2019 and, is anticipated to continue the same at a remarkable CAGR of 12.4% during the forthcoming period. Antidiabetic Drug segment is subclassified into Alpha-glycosidase Inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, Meglitinides, DPP-IV (Dipeptidyl Peptidase) inhibitors, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors and Thiazolidinedione. It is also expected to grow at a moderate rate during the projected period. 

Based on the administration route, the market is subdivided into Insulin Syringe/Insulin Pen, Insulin Pump, Intravenous Infusion and Oral. The Insulin Pump segment is anticipated to register strong growth with CAGR of 11% during the forthcoming period.

Based on region, Global Antidiabetics Market is segmented by key regions— North America, Europe, Asia Pacific, South America, and the Middle East & Africa. 

Recent Development

• In December 2019, Mankind Pharmaceuticals signed a collaborative marketing agreement with Glenmark Pharmaceuticals for Remoglifozin, an antidiabetic drug, in India. This has allowed both companies to expand their business in the Asia Pacific region.

• In February 2018, Cipla collaborated with Novartis and Johnson & Johnson to market their antidiabetic drugs to strengthen its market position by widening its base.

Scope of the Report 

By Product

Ø  Insulin 

ü  Rapid Acting

ü  Long Acting

ü  Premixed Insulin

ü  Short Acting

ü  Intermediate Acting 

Ø  Drug Class

ü  Alpha-Glucosidase Inhibitors

ü  Biguanides

ü  Sulphonylureas

ü  GLP-1 Agonist

ü  Meglitinides

ü  DPP-4 Inhibitors

ü  SGLT-2

ü  Thiazolidinedione

By Patient Population

Ø  Pediatric

Ø  Adult

Ø  Geriatric

By Route of Administration 

Ø  Insulin Syringe/Insulin Pen

Ø  Insulin Pump

Ø  Intravenous Infusion

Ø  Oral

By Region

Ø  North America

Ø  Europe 

Ø  Asia Pacific

Ø  South America

Ø  Middle East & Africa

The objective of the Study:

Ø  To analyze and estimate the Global Electric Boat Market size, in terms of value.

Ø  To examine the market segmentation carefully and estimate the market size, in terms of value, based on the region by segmenting the Global Antidiabetics Market into five regions, namely, North America, Europe, Asia Pacific, Rest of the World and their leading countries.

Ø  To outline, categorize and project the Global Antidiabetics Market based on Product, Patient Population, Route of Administration and Region.

Ø  To examine competitive developments in product and devices used for administration across different age-groups within the Global Antidiabetics Market.

Ø  To highlight market dynamics such as drivers, restraints, opportunities, and challenges and their impact.

Ø  To provide a detailed competitive landscape, including major players, their strategic profiles, and market shares.

Business Questions Answered by the Report:

Ø  How will the market drivers, restraints, and opportunities affect the market dynamics?

Ø  What will be the market size in terms of value and volume and market statistics with a detailed classification?

Ø  Which segment dominates the market or region, and which one will be the fastest-growing, and why?

Ø  Who are the key players in the market, and what is their share?

Ø  What is the strategy adopted by key players, and how does it affect the existing and new players?

Customization Scope for the Client:

Client satisfaction is our first and last priority, and that is why BlueWeave Consulting offers customization as per client’s specific needs. The following customization options are available for the report:

Ø  Additional Company Information

Ø  Detail Analysis of five additional companies

Ø  Additional country analysis

Ø  Detailed segment analysis

1.    Research Framework

1.1.     Research Objective

1.2.     Product Overview

1.3.     Market Segmentation

2.    Research Methodology

2.1.     Qualitative Research

2.1.1. Primary & Secondary Sources

2.2.     Quantitative Research

2.2.1. Primary & Secondary Sources

2.3.     Market Breakdown & Data Triangulation

2.3.1. Secondary Research

2.3.2. Primary Research

2.4.     Breakdown of Primary research respondent, By Region

2.5.     Assumption & Limitation

3.    Executive Summary

4.    Global Antidiabetics  market Industry Insights

4.1.     DROC Analysis

4.1.1. Growth Drivers

4.1.2. Restraint

4.1.3. Opportunities

4.1.4. Challenges

4.2.     Technological Landscape/Recent Development

4.3.     Regulatory Framework

4.4.     Company Market Share Analysis, 2019

4.5.     Porter’s Five Forces Analysis

4.5.1. Bargaining Power of Suppliers

4.5.2. Bargaining Power of Buyers

4.5.3. Threat of New Entrants

4.5.4. Threat of Substitutes

4.5.5. Intensity of Rivalry

4.6.     Impact of COVID 19

5.    Global Antidiabetics  market Overview

5.1.     Market Size & Forecast by Value, 2016-2026

5.1.1. By Value (USD Million)

5.2.     Market Share & Forecast

5.2.1. By Product

5.2.1.1.     Insulin

5.2.1.1.1.          Rapid acting analog

5.2.1.1.2.          Long acting analog

5.2.1.1.3.          Short acting analog

5.2.1.1.4.          Intermediate acting insulin

5.2.1.1.5.          Others

5.2.1.2.     Drug class

5.2.1.2.1.          Alpha glucosidase inhibitors

5.2.1.2.2.          Biguanides

5.2.1.2.3.          Sulphonylureas

5.2.1.2.4.          GLP-1 (Glucagon like peptide) agonists

5.2.1.2.5.          others

5.2.2. By Patient Population

5.2.2.1.       Pediatric

5.2.2.2.       Adult

5.2.2.3.       Geriatric

5.2.3. By Route of Administration

5.2.3.1.       Insulin syringe/ Insulin pen

5.2.3.2.       Insulin pump

5.2.3.3.       Intravenous infusion

5.2.3.4.       Oral

5.2.3.5.       Others

5.2.4. By Region

5.2.4.1.   North America

5.2.4.2.   Europe

5.2.4.3.   Asia Pacific

5.2.4.4.   Latin America

5.2.4.5.   Middle East & Africa

6.    North America Antidiabetics Market

6.1.     Market Size & Forecast by Value, 2016-2026

6.1.1. By Value (USD Million)

6.2.     Market Share & Forecast

6.2.1. By Product

6.2.2. By Patient Population

6.2.3. By Route of Administration

6.2.4. By Country

6.2.4.1.     United States

6.2.4.2.     Canada

7.    Europe Antidiabetics market

7.1.     Market Size & Forecast by Value, 2016-2026

7.1.1. By Value (USD Million)

7.2.     Market Share & Forecast

7.2.1. By Product

7.2.2. By Patient Population

7.2.3. By Route of Administration

7.2.4. By Country

7.2.4.1.     Germany

7.2.4.2.     United Kingdom

7.2.4.3.     France

7.2.4.4.     Italy

7.2.4.5.     Spain

7.2.4.6.     Rest of Europe

8.    Asia Pacific Antidiabetics Market

8.1.     Market Size & Forecast by Value, 2016-2026

8.1.1. By Value (USD Million)

8.2.     Market Share & Forecast

8.2.1. By Product

8.2.2. By Patient Population

8.2.3. By Route of Administration

8.2.4. By Country

8.2.4.1.       India

8.2.4.2.       China

8.2.4.3.       Japan

8.2.4.4.       South Korea

8.2.4.5.       Rest of Asia Pacific

9.    Latin America Antidiabetics Market

9.1.     Market Size & Forecast by Value, 2016-2026

9.1.1. By Value (USD Million)

9.2.    Market Share & Forecast

9.2.1.1.       By Product

9.2.1.2.       By Patient Population

9.2.1.3.       By Route of Administration

9.2.1.4.       By Country

9.2.1.4.1.          Brazil

9.2.1.4.2.          Mexico

9.2.1.4.3.          Rest of Latin America

10.Middle East & Africa Antidiabetics Market

10.1.   Market Size & Forecast by Value, 2016-2026

10.1.1.              By Value (USD Million)

10.2. Market Share & Forecast

10.2.1.1.    By Product

10.2.1.2.    By Patient Population

10.2.1.3.    By Route of Administration

10.2.1.4.    By Country

10.2.1.4.1.       Saudi Arabia

10.2.1.4.2.       UAE

10.2.1.4.3.       South Africa

10.2.1.4.4.       Rest of Middle East & Africa

11.Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

11.1. Sanofi Aventis

11.2. Takeda Pharmaceuticals

11.3. Eli Lilly

11.4. Oramed Pharmaceuticals Inc.

11.5. Merck & Co. Inc.

11.6. Novo Nordisk

11.7. Bristol-Myers Squibb

11.8. Halozyme Therapeutics

11.9. Pfizer

11.10. Novartis AG

11.11. Takeda Pharmaceutical

11.12.  Johnson & Johnson

11.13. Other Prominent Players

* Financial details in case of unlisted companies will be available as per data availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable.